Patents by Inventor Claes Wahlestedt

Claes Wahlestedt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210008005
    Abstract: The present invention provides methods and compositions for the treatment of mucopolysaccharidoses (MPS).
    Type: Application
    Filed: September 15, 2020
    Publication date: January 14, 2021
    Inventors: Shaun Brothers, Claes Wahlestedt, Claude Henry Volmar
  • Patent number: 10472627
    Abstract: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: November 12, 2019
    Assignee: The Scripps Research Institute
    Inventor: Claes Wahlestedt
  • Publication number: 20190247302
    Abstract: The disclosure provides an ophthalmic formulation comprising a bromodomain inhibitor, a polar aprotic solvent (e.g., dimethyl sulfoxide (DMSO)), polysorbate, salt, and Captisol, as well as a method of treating or preventing ophthalmic inflammation in a subject in need thereof comprising locally administering the formulation to the eye of the subject.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 15, 2019
    Applicant: University of Miami
    Inventors: Robert B. Levy, Victor L. Perez, Claes Wahlestedt, Casey O. Lightbourn, Sabrina Copsel, Henry Barreras, Stephanie Duffort
  • Publication number: 20190076376
    Abstract: The present invention provides methods and compositions for the treatment of mucopolysaccharidoses (MPS).
    Type: Application
    Filed: July 8, 2016
    Publication date: March 14, 2019
    Inventors: Shaun Brothers, Claes Wahlestedt, Claude Henry Volmar
  • Publication number: 20180148721
    Abstract: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).
    Type: Application
    Filed: September 26, 2017
    Publication date: May 31, 2018
    Inventor: Claes Wahlestedt
  • Patent number: 9803195
    Abstract: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: October 31, 2017
    Assignee: The Scripps Research Institute
    Inventor: Claes Wahlestedt
  • Patent number: 9738894
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: August 22, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Publication number: 20170009237
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.
    Type: Application
    Filed: March 28, 2016
    Publication date: January 12, 2017
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Patent number: 9297010
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 29, 2016
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Publication number: 20140235844
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.
    Type: Application
    Filed: February 11, 2014
    Publication date: August 21, 2014
    Applicant: Santaris Pharma A/S
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Patent number: 8653252
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: February 18, 2014
    Assignee: Santaris Pharma A/S
    Inventors: Joachim Elmén, Claes Wahlestedt, Zicai Liang, Anders Malling Sørensen, Henrik Ørum, Troels Koch
  • Publication number: 20130053428
    Abstract: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).
    Type: Application
    Filed: July 31, 2012
    Publication date: February 28, 2013
    Applicant: The Scripps Research Institute
    Inventor: Claes WAHLESTEDT
  • Patent number: 8288354
    Abstract: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: October 16, 2012
    Assignee: The Scripps Research Institute
    Inventor: Claes Wahlestedt
  • Publication number: 20090258925
    Abstract: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).
    Type: Application
    Filed: December 28, 2006
    Publication date: October 15, 2009
    Inventor: Claes Wahlestedt
  • Patent number: 7528229
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: May 5, 2009
    Assignee: National Research Council of Canada
    Inventors: Shen Shi-Hsiang, Ahmad Sultan, Claes Wahlestedt, Philippe Walker
  • Patent number: 7510846
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: March 31, 2009
    Assignee: National Research Council of Canada
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Publication number: 20080249039
    Abstract: The present invention is directed to modified siRNA which are significantly impaired in their ability to support cleavage of mRNA when incorporated into a RISC complex. Such modified siRNA may be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the modified siRNA comprises a sense strand and an antisense strand, wherein the sense strand contains a modified RNA nucleotide in at least one of positions 8-14, calculated from the 5?-end.
    Type: Application
    Filed: January 28, 2005
    Publication date: October 9, 2008
    Applicant: SANTARIS PHARMA A/S
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Henrik Orum, Troels Koch
  • Patent number: 7407761
    Abstract: The present invention is directed to methods for assaying a test compound's ability to alter the expression of novel receptor for galanin which has been designated as galanin receptor 2. The invention also encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to additional methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: August 5, 2008
    Assignee: National Research Council of Canada
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Patent number: 7375207
    Abstract: The present invention is directed to galanin receptor 2 (GAL-R2) proteins and nucleic acids.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: May 20, 2008
    Assignee: AstraZeneca A.B.
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Publication number: 20070191294
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.
    Type: Application
    Filed: March 22, 2004
    Publication date: August 16, 2007
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders Sorensen, Henrik Orum, Troels Koch